BioCentury | Jun 30, 2017
Clinical News
Xenetic begins Phase II of XBIO-101 in endometrial cancer
...increases PGR expression. Xenetic has worldwide rights to develop and commercialize XBIO-101 from Pharmsynthez JSC (MICEX:LIFE). Pharmsynthez...
...the Commonwealth of Independent States (CIS), excluding oncology indications (see BioCentury, Dec. 21, 2015 ). Pharmsynthez JSC...
...disease and overall survival (OS) Status: Phase II started Milestone: NA Julian Zhu Xenetic Biosciences Inc. Progesterone receptor (PGR) Pharmsynthez JSC sodium...
...the Commonwealth of Independent States (CIS), excluding oncology indications (see BioCentury, Dec. 21, 2015 ). Pharmsynthez JSC...
...disease and overall survival (OS) Status: Phase II started Milestone: NA Julian Zhu Xenetic Biosciences Inc. Progesterone receptor (PGR) Pharmsynthez JSC sodium...